Bill
SB 5814
Overview: SB 5814, "Concerning coverage of prescription drugs for advanced metastatic cancer", public hearing in the Senate Committee on Health & Long Term Care at 8:00 AM, introdu
Overview: SB 5814, "Concerning coverage of prescription drugs for advanced metastatic cancer", public hearing in the Senate Committee on Health & Long Term Care at 8:00 AM, introduced on April 16, 2025.
Purpose and Intent: This bill aims to improve access to prescription drug coverage for individuals with advanced metastatic cancer. It seeks to ensure that health plans provide comprehensive coverage for the latest FDA-approved treatments, including off-label use of drugs, to help manage the disease and improve quality of life.
Key Provisions:
- Requires health plans to cover any FDA-approved prescription drug for the treatment of advanced metastatic cancer, regardless of whether the drug is being used for an off-label purpose
- Prohibits health plans from imposing step therapy or prior authorization requirements for these prescription drugs
- Mandates that health plans provide coverage for routine patient costs associated with clinical trials for advanced metastatic cancer treatments
Affected Parties and Impacts: The bill would directly benefit individuals with advanced metastatic cancer by improving their access to the latest and most effective treatments. Health insurance providers would be required to adjust their coverage policies to comply with the new requirements.
Procedural and Timeline Considerations: The bill is currently in the public hearing stage in the Senate Committee on Health & Long Term Care, and its progress will be monitored as it moves through the legislative process.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
